Ibrutinib Displays Atrial-Specific Toxicity in Human Stem Cell-Derived Cardiomyocytes

Ibrutinib (IB) is an oral Bruton's tyrosine kinase (BTK) inhibitor that has demonstrated benefit in B cell cancers, but is associated with a dramatic increase in atrial fibrillation (AF). We employed cell-specific differentiation protocols and optical mapping to investigate the effects of IB an...

Descripción completa

Detalles Bibliográficos
Autores principales: Shafaattalab, Sanam, Lin, Eric, Christidi, Effimia, Huang, Haojun, Nartiss, Yulia, Garcia, Analucia, Lee, Jeehon, Protze, Stephanie, Keller, Gordon, Brunham, Liam, Tibbits, Glen F., Laksman, Zachary
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524928/
https://www.ncbi.nlm.nih.gov/pubmed/31031187
http://dx.doi.org/10.1016/j.stemcr.2019.03.011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524928/
https://www.ncbi.nlm.nih.gov/pubmed/31031187
http://dx.doi.org/10.1016/j.stemcr.2019.03.011

Ejemplares similares